clinical trial · NCT04470908
The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males
BeiGene·phase1·completed·n = 13
HealthyMaleZanubrutinibRifabutin
brief summary
The primary objective of this study was to determine the effect of the moderate cytochrome P450 3A (CYP3A) inducer rifabutin on the pharmacokinetics (PK) of zanubrutinib in healthy males.
started
Jul 29, 2020
primary completion
Nov 10, 2020
completion
Nov 10, 2020
last updated
Oct 26, 2024
official title
A Phase 1, Open-label, Fixed-sequence Study to Investigate the Effect of the Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Male Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol